James Noble becomes full-time CEO of Adaptimmune
This article was originally published in Scrip
Adaptimmune, a biotechnology company focused on the use of engineered T cells to treat cancer, has named James Noble full-time CEO – effective 31 March 2014. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director. Meanwhile, Dr Jonathan Knowles, currently executive chair of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore until the company's board appoints a permanent replacement. The move comes as both companies are "at the stage where they each require a full-time CEO to lead further development," said Adaptimmune.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.